We are international

IMF Myeloma Minute

IMF News:

IMF Heads to Florida for 43rd Annual Meeting of American Society of Hematology (ASH)
This year's ASH Annual Meeting will take place in Orlando, FL on December 7-11. As always, the IMF will be on-site, manning an information booth in our ongoing effort to raise awareness of myeloma and the many different services offered by the IMF. This year's meeting will include a record number of presentations on multiple myeloma. Forty-seven abstracts have been selected for oral presentation and more than 200 will be presented in poster format. A vast range of topics will be covered. In the coming weeks, the IMF will provide details of the most exciting findings, with commentaries from our various scientific advisors.

Some of the most clinically relevant presentations include:

  • Results of the PS-341 multi-center, Phase II trial in patients with relapsing and refractory myeloma.
  • Results of the new thalidomide analog, IMID 501, also known as Revimid.

IMF to Kick off 2002 with Dallas Patient & Family Seminar!
The IMF is rounding up IMFers in the "Lone Star State" on January 11th and 12th, 2002 for an always informative Patient & Family Seminar. These seminars are especially beneficial for newly-diagnosed patients and their families, as it's an excellent opportunity to learn the latest in the treatment and management of myeloma from a panel of world-renowned myeloma specialists. Whether you're newly-diagnosed, or a 10-year survivor, you're sure to learn something new! Confirmed faculty include Drs. Durie, Greipp, Mehta, Mundy, Singhal and Stone. Click here for more information, or to register online. You may also register via phone by calling (800) 452-CURE.

Myeloma in the News:

November 7, 7:00 am Eastern Time
(AnorMED Press Release)
AnorMED announces AMD-3100 mobilizes stem cells: Study Results to be Presented at Upcoming American Society of Hematology Meeting December 10th 2001, Orlando Florida

A note about AMD-3100, provided by Dr. Brian G.M. Durie:
"The AnorMED product, AMD-3100 is a chemokine inhibitor which rapidly mobilizes bone marrow stem cells into the blood circulation. Currently this process is achieved using a combination of Cytoxin (chemotherapy) plus the growth factor, Neuopgen (G-CSF). Phase I trial results combining AMD-3100 with Neupogen will be presented at the upcoming ASH meeting and should serve as the basis for more detailed future studies."

News You Can Use:

Multiple Myeloma: New Insights and Therapeutic Approaches
By Drs. Anderson, Kyle, Dalton, Berenson and colleagues.
A review discussing the evolution of novel diagnostic strategies for myeloma based upon increased understanding of basic disease pathogenesis. Although myeloma has remained an incurable illness to date, these new developments will derive treatments to improve outcome and achieve eventual cure.

Understanding Cancer Tests
(Provided by CancerSource.com)
Doctors use tests like mammography, magnetic resonance imaging (MRI), and computed tomography (CT) scans to help them screen for, diagnose, treat, and monitor cancer. If you have been diagnosed with cancer, you may have had one or more of these tests. You may have wondered why you had specific tests and not others or what exactly the doctor was looking for.

Understanding Research Studies
(Provided by CancerSource.com)
"A new study finds that eating nine vegetables daily prevents colon cancer." "Results of a clinical trial show tamoxifen is effective in preventing breast cancer in high-risk women." Do you wonder what a clinical trial or an epidemiological study is after hearing these headlines?

Clinical Trials:

Combination Chemotherapy With or Without Thalidomide in Treating Patients With Refractory Multiple Myeloma

Editor's Note:
In the October 2001 issue of Myeloma Today, Dr. Brian G.M. Durie commented on an article published in the journal Blood regarding findings that patients taking thalidomide along with other chemotherapy (particularly Adriamycin) were more likely to develop episodes of deep vein thrombosis, also known as phlebitis. Dr. Durie stresses that, with regards to clinical trials, it is very important to evaluate the efficacy and toxicity of the treatment under investigation. To read Dr. Durie's comments in full, please click here.

Expression of the Genome in Lymphoid Malignancies

Editor's Note:
In addition to the genome studies being conducted by the NCI, several myeloma centers are now doing detailed genomic and proteinomic studies specifically in myeloma. Results of such studies are to be presented at the upcoming ASH meeting.

Don't Forget:

IMF Holiday Greeting Cards are Selling Fast!

Spread some cheer this holiday season while supporting the IMF! Thanks to the artistic talents of our Jr. IMFers, we can now offer Christmas and Holiday greeting cards! Both Christmas and Holiday cards feature two different designs and are available in packages of 10 cards (five of each design) for a $20 donation. Pre-ordering is available now. Order online by clicking here, or call the IMF at (800) 452-CURE. Cards are in stock and ready for delivery. Quantities are limited.

Tell A Friend...

The Myeloma Minute is a great way to stay abreast of the latest developments within the myeloma community. We hope you'll share this information with friends, family members and physicians and encourage them to sign up for their own copy by forwarding this message. New users can register by clicking here. You can also view back issues of Myeloma Minute online.

If you no longer wish to receive the Myeloma Minute, please visit the log-in page, enter your email address, password, first and last name and click the "unsubscribe" button at the bottom of the page.

 related articles